Pharmaceutical giant Johnson & Johnson has agreed to pay as much as $2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal. The lawsuit claims Johnson & Johnson paid kickbacks to a company that provided prescription drugs to nursing home patients in order to increase the sales of Risperdal, a drug approved to treat symptoms of schizophrenia and bipolar disorder. The drug has been associated with an increased risk of death in elderly people with dementia. The settlement will include a $400 million criminal fine. The final amount Johnson & Johnson pays will be determined by how many ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.